Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | CDC42 | P60953 | 1/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448280 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL29993492 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL554068 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL29993475 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL13810650 | 0.89 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL12744140 | 0.88 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL11470486 | 0.85 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL10025981 | 0.83 | AKR1B1 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL1217681 | 0.83 | AKR1B1 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| Ammonia Solution, Strong SCHEMBL11721423 | 0.83 | AKR1C3 (0.67) | AKR1C3AKR1C2PTGS2PTGS1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420850-B2 | Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers | Iberhospitex, S.A (ES) | 2013-04-16 | — | — | US | disclosed |
| US-8420850-B2 | Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers | Iberhospitex, S.A (ES) | 2013-04-16 | — | — | US | disclosed |
| US-20120059117-A1 | COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS | IBERHOSPITEX, S.A. | 2012-03-08 | — | — | US | disclosed |
| US-20120059117-A1 | COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS | IBERHOSPITEX, S.A. | 2012-03-08 | — | — | US | disclosed |
| WO-2011141341-A1 | COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS | IBERHOSPITEX, S.A. (ES) | 2011-11-17 | — | — | WO | disclosed |
| US-5250693-A | Lipoxygenase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| US-5208344-A | Benzothiazole derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-05-04 | — | — | US | disclosed |
| US-5084575-A | Drugs for the treatment of rhinitis, asthma and skin disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| US-4960892-A | ENZYME INHIBITOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0301813-B1 | NAPHTHALENEPROPIONIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-08-08 | — | — | EP | disclosed |
| EP-0301813-A1 | Naphthalenepropionic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059117-A1 | COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS | PUF60, UMPS, UGP2 | AKR1C3 3851/4885AKR1C2 2962/4885PTGS2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.